Table 1.
Adenovirus vector vaccines - reported events and current status.
| Manufacturer | Vaccine | Vector | Doses | Events | Current status |
|---|---|---|---|---|---|
| AstraZeneca-Oxford vaccine group | Vaxzevria | ChAdOx1 | 2 | Signal assessment report (March 12, 2021) | Suspended in Denmark. Recommended for only older age groups in UK, Belgium, Italy, Spain, Germany, France, Netherlands, Finland, Sweden. |
| CVA (n = 57), MI (n = 34), PE (n = 22), monoplegia (n = 31), DVT (n = 15), Ischemic stroke (n = 11), CVT (n = 4), DIC (n = 1) | |||||
| 169 CVT | |||||
| 53 SVT (until 4th April 2021) | |||||
| Janssen (Johnson and Johnson) | Janssen | Ad26 | 1 | 6 CVT | Currently suspended in EU, South Africa and USA. |
| AstraZeneca-Oxford vaccine group | Covishield | ChAdOx1 | 2 | None confirmed-3 deaths with possible temporal relationship (1 death associated with thrombocytopenia and stroke) | Unrestricted use in India. |
| Gamaleya research institute of epidemiology and microbiology | Sputnik V | Ad26 and Ad5 | 2 | DVT (1) | Approved for emergency use In 62 countries, Rolling review in EU. Currently in use in Russia, Armenia, Belarus, Guinea, Hungary, Iran, Kazakhstan, Kenya, Laos, Lebanon, Nicaragua, Pakistan, Paraguay, Serbia, Syria, Tunisia, UAE, Venezuela. |
| Cerebral circulatory failure (1) | |||||
| TIA (1) | |||||
| vascular encephalopathy (1) | |||||
| CanSino biologics-Beijing Institute of biotechnology | Convidecia | Ad5 | 1 | None reported from interim analysis of Phase-III trial | Approved for use in China, Hungary, Mexico, Chile and Pakistan. Currently in use in China, Mexico. |
CVA = Cerebrovascular Accident, MI = Myocardial Infarction, PE = Pulmonary Embolism, DVT = Deep Vein Thrombosis, CVT = Cerebral Vein Thrombosis, DIC=Disseminated Intravascular Coagulation, SVT = Splanchnic Vein Thrombosis, TIA = Transient Ischemic Attack, Ad = Adenovirus.